These hybridomas (“HYBRIDOMAS”) and the neural-specific monoclonal antibodies (“ANTIBODIES”) that the HYBRIDOMAS produce (collectively the “MATERIALS”) are the property of The Regents of the University of California on behalf of its Davis campus (“THE REGENTS”) or donors (“DONORS”) who have donated MATERIALS for distribution to academic and non-profit research institutions (“USERS”) by the Mutant Mouse Resource and Research Center at the University of California, Davis (“MMRRC”) from the UC Davis/NIH NeuroMab Facility. Use of the MATERIALS is subject to the USAGE RESTRICTIONS below. For other uses, including commercial use, please contact THE REGENTS for appropriate licenses. THE REGENTS and/or DONORS retain ownership of the MATERIALS, including any MATERIALS in any substances created by USERS that contain or incorporate the MATERIALS (“MODIFICATIONS”). USERS are responsible for ensuring that all relevant licenses are obtained for any use of these MATERIALS.
BY ACCEPTING OR USING THESE MATERIALS, YOU REPRESENT THAT YOU HAVE THE AUTHORITY TO ENTER INTO THIS AGREEMENT ON BEHALF OF YOUR INSTITUTION AND THAT YOUR INSTITUTION AGREES TO BE BOUND BY THE CONDITIONS OF THIS AGREEMENT. You may refuse to accept the conditions of this notice by destroying the unused MATERIALS.
The MATERIALS are distributed for non-commercial research purposes only. USERS will not sell or use the MATERIALS or any MODIFICATIONS for commercial purposes. USERS will not attempt to clone or otherwise determine the nucleic acid or amino acid sequences of the MATERIALS.
USERS will not distribute the MATERIALS to any third parties for any purposes, except that a USER may transfer HYBRIDOMAS to a third party vendor for the sole purpose of producing ANTIBODIES that are to be used only by that USER. Such third party vendors are prohibited from sending ANTIBODIES or HYBRIDOMAS to any party other than the USER. USERS will refer any requests for the MATERIALS to the MMRRC. USERS may transfer, after notifying MMRRC in writing, MODIFICATIONS at no cost, other than a transmittal fee solely to reimburse the USERS for their preparation and distribution costs, to other scientists for non-commercial research purposes only if the recipient of the MODIFICATIONS receives a copy of this notice and agrees to be bound by its terms and only if the MODIFICATIONS are modified versions of the ANTIBODIES.
THE MATERIALS ARE NOT FOR USE IN HUMAN SUBJECTS.
USERS will cite the UC Davis/NIH NeuroMab Facility and the MMRRC in any publication(s) describing the research utilizing the MATERIALS. The suggested acknowledgment statement is as follows: The hybridoma cell line [clone ID, RRID: MMRRC____] which produced monoclonal antibody [RRID: AB____] was donated to the MMRRC on behalf of the UC Davis/NIH NeuroMab Facility by James Trimmer, Ph.D., University of California Davis.
Any MATERIALS provided pursuant to this Research License Agreement are understood to be experimental in nature and may have hazardous properties. THE REGENTS AND THE UNITED STATES GOVERNMENT MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIALS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. Nothing in this Agreement grants by implication, estoppel, or otherwise any rights in the intellectual property of THE REGENTS except as explicitly set forth herein.
Unless prohibited by law, USERS assume all liability for claims for damages against it by third parties which may arise from the USERS’ use, storage or disposal of the MATERIALS. To the extent permitted by law, USERS will hold harmless, defend, and indemnify THE REGENTS and the United States Government against any claims, costs or other liabilities which may arise as a result of the USERS’ use, storage or disposal of the MATERIALS. However, if the USERS are from a U.S. federal agency, indemnification is prohibited per the Anti-Deficiency Act (31 U.S.C. 1341) and the USERS assume liability only to the extent provided under the Federal Tort Claims Act (28 U.S.C. Chapter 171).Return